C section News and Research

RSS

Redpoint Bio decreases third quarter net loss to $1.8 million

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the three months and nine months ended September 30, 2010.

9 Nov 2010

Excessive texting and networking raise new health concerns for teens

Texting while driving can be a deadly combination for teenagers. Yet, new data released today reveal that the dangers of excessive texting among teens are not limited to the road. Hyper-texting and hyper-networking are now giving rise to a new health risk category for this age group.

9 Nov 2010

New research shows psychoprophylaxis can help tocophobic men

New research, presented in a doctoral thesis from the Swedish medical university Karolinska Institutet, shows that psychoprophylaxis can help men with tocophobia (fear of childbirth).

9 Nov 2010

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Inspiration Biopharmaceuticals, Inc. today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).

9 Nov 2010

Calypte receives $244,479 tax credit under QTDP program

Calypte Biomedical Corporation, the developer, manufacturer and marketer of the Aware HIV-1/2 OMT (oral fluid) HIV test, announced today that it has been awarded a tax credit of $244,479 under U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

AAGL recommends vaginal or laparoscopic hysterectomies

Approximately 600,000 hysterectomies are performed in the United States annually to treat benign disorders of the pelvis. More than two-thirds are performed through an abdominal incision. In an evidence-based position statement published online today in The Journal of Minimally Invasive Gynecology, the AAGL, a medical specialty society of over 5,000 gynecologic surgeons, advocates the practice of performing these procedures vaginally or laparoscopically in a minimally invasive manner, thus reducing morbidity and facilitating a faster recovery period.

8 Nov 2010

Pervasis receives $920,000 in grants under QTDP program

Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years.

8 Nov 2010

ST Cardio Technologies receives $244,479 QTDP Program grant to develop Z6 Cardiac Stimulator

ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.

8 Nov 2010

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

CombiMatrix receives $488,958 grant under QTDP program

CombiMatrix Corporation a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

4 Nov 2010

New findings on mitochondrial haplogroups associated with successful aging to be presented at ASHG Meeting

Thousands of the world's top scientists and clinicians in the human genetics field will convene to present their latest research findings at the American Society of Human Genetics (ASHG) 60th Annual Meeting, on November 2-6, 2010, in Washington, D.C.

4 Nov 2010

Researchers to develop multidisciplinary approach to help kidney disease patients adhere to BP medications

Researchers at the University of Cincinnati (UC) and the Cincinnati Veterans Affairs (VA) Medical Center have found that about one-third of chronic kidney disease patients who are prescribed therapies for high blood pressure do not often adhere to treatments.

4 Nov 2010

NinePoint Medical awarded $250,000 grant from Qualifying Therapeutic Discovery Project Program

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has been awarded a grant of approximately $250,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The QTDP's grants and tax credits are provided under the new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.

4 Nov 2010

pSivida awarded $489,000 grant under IRS Qualifying Therapeutic Discovery Project

pSivida Corp., a leader in the development of sustained release drug delivery products for the treatment of back-of-the-eye disease including the product candidate Iluvien™ for the treatment of Diabetic Macular Edema, today announced that it has been awarded two grants totaling $489,000 under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants were awarded to pSivida to help fund further research on new generations of the company's drug delivery technologies targeting ophthalmic diseases.

4 Nov 2010

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Omega third quarter net income decreases from $21.1 million to $17.0 million

Omega Healthcare Investors, Inc. today announced its results of operations for the quarter ended September 30, 2010.

4 Nov 2010

C section News and Research

Redpoint Bio decreases third quarter net loss to $1.8 million

Excessive texting and networking raise new health concerns for teens

New research shows psychoprophylaxis can help tocophobic men

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Calypte receives $244,479 tax credit under QTDP program

XenoPort third quarter net loss decreases to $19.9 million

New findings could help scientists devise optimal therapies for Friedreich's ataxia

AAGL recommends vaginal or laparoscopic hysterectomies

Pervasis receives $920,000 in grants under QTDP program

ST Cardio Technologies receives $244,479 QTDP Program grant to develop Z6 Cardiac Stimulator

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Skin to blood transformation in the lab

CombiMatrix receives $488,958 grant under QTDP program

New findings on mitochondrial haplogroups associated with successful aging to be presented at ASHG Meeting

Researchers to develop multidisciplinary approach to help kidney disease patients adhere to BP medications

NinePoint Medical awarded $250,000 grant from Qualifying Therapeutic Discovery Project Program

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

pSivida awarded $489,000 grant under IRS Qualifying Therapeutic Discovery Project

Cocrystal receives $733,438 in grants from QTDP program

Omega third quarter net income decreases from $21.1 million to $17.0 million

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News